

Dates and times\* for accepted abstracts and presentations of note are as follows:

\*Times listed are in PT

Oral Presentations	
Abstract Details	Titles
<b>Axicabtagene ciloleucel</b>	
Abstract #526 Sunday, December 8, 2024 10:15 AM Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Abstract #527 Sunday, December 8, 2024 10:30 AM Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26	Real-world Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-cell Lymphoma (LBCL) in the US: a CIBMTR Report
Abstract #609 Sunday, December 8, 2024 12:30 PM Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4	Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Abstract #864 Monday, December 9, 2024 4:00 PM Marriott Marquis San Diego Marina, Marriott Grand Ballroom 11-13	5-Year Follow-Up Analysis From ZUMA-5: a Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
<b>Brexucabtagene autoleucel</b>	
Abstract #748 Monday, December 9, 2024 11:15 AM Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9	Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
<b>Anitocabtagene autoleucel</b>	
Abstract #1031 Monday, December 9, 2024 5:30 PM Marriott Marquis San Diego Marina, Pacific Ballroom 24-26	Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Preliminary Results From the iMMagine-1 Trial  *Led by Arcellx
<b>Poster Presentations</b>	
<b>Axicabtagene ciloleucel</b>	
Abstract #2367 Saturday, December 7, 2024 5:30 PM - 7:30 PM San Diego Convention Center, Halls G-H	Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort
Abstract #3347 Sunday, December 8, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	Improvements in Axicabtagene Ciloleucel Manufacturing Result in High Delivery Success and More Predictable Turnaround Time for Patients With Relapsed/Refractory Large B-Cell Lymphoma
Abstract #4368 Monday, December 9, 2024 6:00 PM - 8:00 PM	Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel

San Diego Convention Center, Halls G-H	
Abstract #5037 Monday, December 9, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany
<b><i>Brexucabtagene autoleucl</i></b>	
Abstract #4388 Monday, December 9, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	Five-Year Outcomes of Patients (Pts) With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated With Brexucabtagene Autoleucl (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
Abstract #5092 Monday, December 9, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	Real-World (RW) Outcomes for Brexucabtagene Autoleucl (Brexu-Cel) Treatment in Patients (Pts) With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) by High-Risk Features and Prior Treatments: Updated Evidence From the CIBMTR <sup>®</sup> Registry
Abstract #4193 Monday, December 9, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	Impact of disease burden, CAR-T expansion, and mononuclear cell recovery on overall response and duration of response in ZUMA-3 pivotal study
<b><i>Anitocabtagene autoleucl</i></b>	
Abstract #4825 Monday, December 9, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	Phase 1 Study of Anitocabtagene Autoleucl for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety With 34-Month Median Follow-up  *Led by Arcellx
<b><i>Kite next generation CAR T-cell therapies</i></b>	
Abstract #3481 Sunday, December 8, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	KITE-753: An Autologous Rapid Manufactured Anti-CD19/CD20 CAR-T Product for the Treatment of B-cell Malignancies
<b>Investigator-Sponsored / Collaboration**</b>	
Abstract #4505 Sunday, December 8, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	Health-related quality of life after Axi-cel as a second-line therapy in patients with high-risk relapsed/refractory large B-cell lymphoma who are ineligible for autologous stem cell transplantation: results of the ALYCANTE phase II trial  *Led by The Lymphoma Study Association
Abstract #4721 Monday, December 9, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis  *Investigator led
Abstract #3734 Sunday, December 8, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucl in Non-Hodgkin's Lymphoma (NHL) - a Large, Multicenter Study  *In collaboration with Sarah Cannon Transplant and Cellular Therapy Network
Abstract #3124 Sunday, December 8, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	CAR T-cells for relapsed/refractory B-cell lymphoma in people living with HIV (PLWH): a LYSA study from the DESCAR-T registry  *Led by The Lymphoma Study Association

Abstract #2031 Saturday, December 7, 2024 6:00 PM - 8:00 PM San Diego Convention Center, Halls G-H	Early MRD detection after CAR-T Associated with Poor Outcome in LBCL  *In collaboration with Dana-Farber Cancer Institute
Abstract #239 Saturday, December 7, 2024 3:00 PM Session: 623 (2:00 - 3:30 PM) Marriot Grand Ballroom 11-13	Outcome of patients with Mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T Study By Lysa Group  *Led by The Lymphoma Study Association
Abstract # Date TBD Time TBD Room TBD	A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older: A Lysa Study from the Descar-T Registry  *Led by The Lymphoma Study Association
<b>Publication Only</b>	
Abstract #7775	Real-World Interim PET/CT Scan Use During Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Abstract #7607	Short-term Costs Associated With Outpatient Use of Axicabtagene Ciloleucel in Second-line Relapsed/Refractory Large B-cell Lymphoma Based on ZUMA-24 Clinical Trial
Abstract #7592	A United States (US) Cost-Effectiveness Analysis of Axicabtagene Ciloleucel Compared to Odronektamab in Third Line or Later (3L+) Diffuse Large B-Cell Lymphoma
Abstract #6962	Treatment Patterns and Outcomes in Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma: Findings from the Flatiron Database
Abstract #7159	In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized by Overexpression of GATA3 Transcript

For more information, including a complete list of abstract titles at the meeting, please visit: <https://ash.confex.com/ash/2024/webprogram/start.html>

\*\*Presentations independently led and sponsored feature Kite CAR T-cell therapies but are not included in total number of Kite accepted abstracts.